Third Harmonic Bio Stock (NASDAQ:THRD)
Previous Close
$12.15
52W Range
$6.45 - $16.94
50D Avg
$13.35
200D Avg
$11.98
Market Cap
$518.17M
Avg Vol (3M)
$198.51K
Beta
2.86
Div Yield
-
THRD Company Profile
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
THRD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ENOB | Renovaro Biosciences Inc. |
| NUVB | Nuvation Bio Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| NXTC | NextCure, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| SNSE | Sensei Biotherapeutics, Inc. |
| GRPH | LENZ Therapeutics, Inc. |
| RLYB | Rallybio Corporation |
| PASG | Passage Bio, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| MACK | Merrimack Pharmaceuticals, Inc. |
| ELYM | Eliem Therapeutics, Inc. |